Pfizer Ignite: Kathy Fernando’s vision for accelerating biotech innovation

Kathy Fernando, the senior vice president, head of Pfizer Ignite and Pfizer CentreOne, has had a professional trajectory marked by pivotal serendipities. One occurred when attending a seminar at the University of Pennsylvania, where she met Dr. Drew Weissman, a prominent immunologist and RNA vaccine researcher. Weissman, along with Katalin Karikó, recently received the Nobel Prize in medicine for discoveries that led to the development of mRNA vaccines against COVID-19.

Hearing Weissman first speak, Fernando recalls being “just blown away” by his scientific creativity. “He just took things to the next level,” she said. She would go on to study under his tutelage, eventually co-authoring a paper with him on HIV that was published in the journal Blood in 2007. The paper explored the potential of mRNA in an HIV vaccine, and the challenges associated with triggering an unintended immune response from the approach. “When you gave mRNA, the bod…

Read more
  • 0

Novo Nordisk stops once-weekly semaglutide kidney outcomes trial early following interim analysis

Novo Nordisk will halt the phase 3b FLOW trial, which investigated the effects of once-weekly injectable semaglutide on kidney outcomes in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD).

The company reached the decision following the recommendation of the independent Data Monitoring Committee (DMC), following an interim analysis that met pre-specified criteria for stopping the trial early for efficacy. The company noted that it would maintain the integrity of the trial data, blinding to the results until the trial’s completion. It plans on announcing results in the first half of 2024.

Semaglutide Sales: 2022 vs H1 2023 google.charts.load('current', {'packages':['corechart']}); google.charts.setOnLoadCallback(drawChart); function drawChart() { var data = google.visualization.arrayToDataTable([ ['Drug Name with Brand', '2022 Sales', 'H1 2023 Sales'], …
Read more
  • 0

Pharma giants make progress in pivot to mRNA technology in race for next-gen influenza vaccines, but hurdles remain

[Image courtesy of Adobe Stock]

mRNA technology helped propel the development of some of the most successful drugs in pharma history — notably, the Comirnaty COVID-19 from Pfizer generated almost $56 billion in 2022 while Moderna’s Spikevax vaccine raked in $18.4 billion. But with demand for COVID-19 vaccines cooling, drug developers are aiming to extend the dominion of mRNA technology to flu vaccines. This month, Moderna and the CureVac/GSK alliance announced promising interim results for their respective flu vaccine candidates. Meanwhile, a year ago, in September 2022, Pfizer announced a phase 3 study for its mRNA-based influenza vaccine. NIH is also developing an mRNA vaccine that promises to provide protection against all known influenza subtypes. A phase 1 study of it is underway.

Sanofi has acknowledged the promise and perils of mRNA flu vaccines

Sanofi, a prominent flu vaccine maker, has acknowledge…

Read more
  • 0

Anti-obesity drugs to command a $44 billion market by 2030

As obesity rates continue to soar across the globe, analysts anticipate that the market for anti-obesity drugs will skyrocket in the coming years. Goldman Sachs projects the market to be worth $44 billion by 2030. That’s an almost 16-fold expansion from its valuation of approximately $2.82 billion in 2022.

Jenny Chang, portfolio manager with Goldman Sachs Asset Management, highlighted the potential of the drug class, which includes Novo Nordisk’s Ozempic (semaglutide) and Wegovy (also semaglutide), as well as Eli Lilly’s tirzepatide. “Some 42% of Americans are obese, and the economic toll is staggering,” she said in a recent video. The investment firm noted that obesity costs the American healthcare system are in the ballpark of $170 billion annually. Furthermore, the obesity epidemic could drag down global GDP by $4 trillion by 2035.

Echoing this sentiment, JPMorgan Chase & Co. believes Novo Nordisk could capture almost half o…

Read more
  • 0